$AB

ALLIANCEBERNSTEIN HOLDING L.P.

No enriched coverage for $AB in the last 7 days.

No SEC Form 4 filings for $AB in the last 30 days.

See all $AB insider activity →
Low

ALLIANCEBERNSTEIN HOLDING L.P. (AB): Ioanis Jorgali, Investors

ALLIANCEBERNSTEIN HOLDING L.P. (AB) filed an SEC Form 8-K — Regulation FD Disclosure. Ioanis Jorgali, Investors 629.213.6139 ioanis.jorgali@alliancebernstein.com Carly Symington, Media 629.213.5568 carly.symington@alliancebernstein.com AB Announces September 30, 2026 Assets Under Management Nashville, TN, October 12, 2026 - AllianceBernstein L.P. (“AB”) and Allian

AB Announces September 30, 2026 Assets Under Management

AllianceBernstein (NYSE: AB) reported a 2% decrease in assets under management to $900 billion in September 2026, driven by market depreciation and net outflows. Institutional channels saw inflows, offset by outflows in Retail and Private Wealth. Quarterly net inflows totaled $6.0 billion. The company issued forward-looking statements with typical cautionary language.

AB Maintained by Evercore ISI Group -- Price Target Lowered to $

Evercore ISI Group maintained an 'Outperform' rating for AllianceBernstein Holding (AB) but lowered its price target from $42.00 to $39.00. AB has a P/E ratio of 10.34x and a GF Score™ of 35/100, indicating mixed performance. Insiders sold $185,850 worth of shares in the last three months.

AB sentiment & insider activity

Recent AB coverage spans financial news, earnings and corporate actions.

What's driving AB

AlphAI scores every news story that mentions AB with an AI model for sentiment and relevance, and aggregates insider trades from ALLIANCEBERNSTEIN HOLDING L.P.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AB

Score
$ABLow

ALLIANCEBERNSTEIN HOLDING L.P. (AB): Ioanis Jorgali, Investors

ALLIANCEBERNSTEIN HOLDING L.P. (AB) filed an SEC Form 8-K — Regulation FD Disclosure. Ioanis Jorgali, Investors 629.213.6139 ioanis.jorgali@alliancebernstein.com Carly Symington, Media 629.213.5568 carly.symington@alliancebernstein.com AB Announces September 30, 2026 Assets Under Management Nashville, TN, October 12, 2026 - AllianceBernstein L.P. (“AB”) and Allian

$ABLow

AB Announces September 30, 2026 Assets Under Management

AllianceBernstein (NYSE: AB) reported a 2% decrease in assets under management to $900 billion in September 2026, driven by market depreciation and net outflows. Institutional channels saw inflows, offset by outflows in Retail and Private Wealth. Quarterly net inflows totaled $6.0 billion. The company issued forward-looking statements with typical cautionary language.

People moves: AllianceBernstein names Onur Erzan as next CEO

AllianceBernstein (AB) named Onur Erzan as its next CEO, effective April 1, 2027. Erzan, currently president, succeeds Seth Bernstein, who retires but remains on AB's board. AB's assets under management are $919 billion, with $169 billion in private wealth. Erzan joined AB in 2021 from McKinsey and has led key initiatives. AB is a subsidiary of Equitable Holdings.

$ABMed

ALLIANCEBERNSTEIN HOLDING L.P. (AB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

ALLIANCEBERNSTEIN HOLDING L.P. (AB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Ioanis Jorgali, Investors 629-213-6139 Ioanis.Jorgali@alliancerbernstein.com Carly Symington, Media (US) 615.417.5701 Carly.Symington@alliancerbernstein.com AllianceBernstein appoints Onur Erzan President & Chief Executive Officer Seth Bernstein to retire as Chief Executive Offic

AB Announces July 31, 2026 Assets Under Management

AllianceBernstein (NYSE: AB) reported preliminary assets under management of $909 billion as of July 31, 2026, up from $906 billion at June 30. The firm cited firmwide net inflows despite unfavorable markets. Institutions saw strong inflows tied to a previously announced $12 billion commercial mortgage loans mandate, Private Wealth had modest inflows, and Retail had outflows.

$ABMedAI 8/10

AB Science raises EUR 14.2m to fund masitinib Phase III, AB8939

AB Science (Euronext Paris: AB) raised EUR 14.2m via a private placement to fund early steps of a strategic plan due in September. The issue created 23.28m new shares; an existing long-term investor provided EUR 12m. Proceeds target AB8939 in AML and masitinib Phase III in ALS. Cash is about EUR 23m, covering needs beyond 12 months.

Related tickers